Raltegravir

Raltegravir

Raltegravir

Min.Order / FOB Price:Get Latest Price

1 Metric Ton

Negotiable

  • Min.Order :1 Metric Ton
  • Purity: 99.0%Min
  • Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram

Keywords

518048-05-0 Raltegravir Raltegravir

Quick Details

  • Appearance:white powder
  • Application:For Pharmacy Chemicals
  • PackAge:As per buyers'
  • ProductionCapacity:10|Metric Ton|Month
  • Storage:Room Temperature
  • Transportation:by sea,air

Superiority:

Product Name: Raltegravir
Synonyms: Raltegravir;N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide;N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide;N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)p;Raltegravir(R&D);Raltegravir(free base);N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-(2-methyl-1,3,4-oxadiazole-5-carboxamido)propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide;N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)am
CAS: 518048-05-0
MF: C20H21FN6O5
MW: 444.42
EINECS:  
Product Categories: API;Isentress;Inhibitors
Mol File: 518048-05-0.mol
Raltegravir Structure
 
Raltegravir Chemical Properties
CAS DataBase Reference 518048-05-0(CAS DataBase Reference)

 

Details:

Product Features Merck's Raltegravir is the first HIV integrase strand transfer inhibitor (referred to as an integrase inhibitor). It is also known as MK-0518, which can treat human immunodeficiency virus (HIV)-1 infection combining with other antiretroviral (ARV) drugs. It slows HIV-1 infection by inhibiting the necessary HIV integrase for viral replication. When raltegravir combines with other anti-HIV drugs, it can reduce the amount of HIV in the blood, while it can increase the number of so-called CD4+ T cells that belong to white blood cells. It helps against other infections. The interaction between raltegravir and ritonavir, efavirenz, tipranavir and tenofovir indicates that there is no drug cross-resistance, and there is a synergistic effect with a variety of drugs. The most common adverse reactions are diarrhea, nausea, headache. In addition, blood tests show that the muscle enzymes abnormally increased in some of patients who taked this drug. 
The above information is edited by the chemicalbook of Kui Ming.
Usage Raltegravir (MK-0518, Isentress) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM, respectively.

 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View